Catridecacog

Catridecacog
Clinical data
Trade names Tretten, NovoThirteen
AHFS/Drugs.com entry
Pregnancy
category
  • US: C (Risk not ruled out)
Routes of
administration
Injection
Legal status
Legal status
Identifiers
ATC code B02BD11 (WHO)
ChemSpider none

Catridecacog (brand name Tretten in the US and NovoThirteen in Europe[1]) is a class of recombinant factor XIII A-subunit based biopharmaceutical medicine, indicated in patients with a rare clotting disorder, congenital factor XIII A-subunit deficiency, which is a kind of Factor XIII deficiency. The medication prevents bleeding in patients with this condition, and has been approved by the U.S. Food and Drug Administration (FDA) for this use in the US in 2014.[2] It was brought to market by Novo Nordisk.[1]

References


This article is issued from Wikipedia - version of the Thursday, April 21, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.